Cardiovascular Clinical Trial - AMGEN - 890 Olpasiran

Cardiovascular

Status:

Open to accrual

ClinicalTrials.gov:

NCT04270760

Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction - DOSE Finding Study

Drug

Olpasiran, Placebo

Phase

II

Condition

Cardiovascular Disease